MML Investors Services LLC raised its holdings in shares of Zoetis Inc (NYSE:ZTS) by 48.0% during the 4th quarter, HoldingsChannel reports. The fund owned 12,903 shares of the company’s stock after purchasing an additional 4,186 shares during the period. MML Investors Services LLC’s holdings in Zoetis were worth $930,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also made changes to their positions in ZTS. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Zoetis during the 4th quarter valued at $108,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis during the 3rd quarter valued at $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the period. Icon Wealth Partners LLC acquired a new position in shares of Zoetis during the 4th quarter valued at $127,000. Finally, Advisory Services Network LLC increased its position in shares of Zoetis by 42.4% during the 4th quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock valued at $175,000 after purchasing an additional 721 shares during the period. 92.45% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have recently issued reports on ZTS shares. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target on the stock. in a research report on Saturday, January 13th. Morgan Stanley upgraded Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research report on Wednesday, November 29th. Craig Hallum reiterated a “buy” rating and set a $85.00 price target (up from $77.00) on shares of Zoetis in a research report on Tuesday, January 2nd. Bank of America lifted their price target on Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Finally, Cantor Fitzgerald set a $85.00 price target on Zoetis and gave the company a “buy” rating in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus target price of $80.28.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.47 EPS. analysts anticipate that Zoetis Inc will post 3.04 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s payout ratio is 22.94%.
In other news, insider Roman Trawicki sold 23,885 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $82.00, for a total value of $1,958,570.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 35,663 shares of the firm’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the sale, the executive vice president now directly owns 49,919 shares of the company’s stock, valued at approximately $4,044,437.38. The disclosure for this sale can be found here. Insiders sold a total of 105,569 shares of company stock worth $8,594,429 over the last 90 days. Insiders own 0.31% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.